Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Unity Biotechnology, Inc. (UBX) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/27/2023 8-K Quarterly results
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., August 8, 2023 --"
08/03/2023 4 Ghosh Anirvan (CEO) has filed a Form 4 on Unity Biotechnology, Inc.
Txns: Sold 581 shares @ $2.94, valued at $1.7k
08/03/2023 144 Form 144 - Report of proposed sale of securities:
08/01/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/01/2023 144 Form 144 - Report of proposed sale of securities:
06/15/2023 4 Ghosh Anirvan (CEO) has filed a Form 4 on Unity Biotechnology, Inc.
Txns: Sold 1,212 shares @ $3.39, valued at $4.1k
05/12/2023 4 Sullivan Lynne Marie (See Remarks) has filed a Form 4 on Unity Biotechnology, Inc.
Txns: Granted 40,000 options to buy @ $2.77, valued at $110.8k
Disposed/sold 24,000 options to buy @ $99.6, valued at $2.4M
Granted 24,000 options to buy @ $2.77, valued at $66.5k
Disposed/sold 12,333 options to buy @ $41.8, valued at $515.5k
Granted 12,333 options to buy @ $2.77, valued at $34.2k
Disposed/sold 20,000 options to buy @ $10.6, valued at $212k
Granted 20,000 options to buy @ $2.77, valued at $55.4k
05/12/2023 4 Nguyen Alexander Hieu (See Remarks) has filed a Form 4 on Unity Biotechnology, Inc.
Txns: Granted 40,000 options to buy @ $2.77, valued at $110.8k
Disposed/sold 2,083 options to buy @ $41.8, valued at $87.1k
Granted 2,083 options to buy @ $2.77, valued at $5.8k
Disposed/sold 18,332 options to buy @ $10.6, valued at $194.3k
Granted 18,332 options to buy @ $2.77, valued at $50.8k
05/12/2023 4 Ghosh Anirvan (CEO) has filed a Form 4 on Unity Biotechnology, Inc.
Txns: Granted 135,000 options to buy @ $2.77, valued at $374k
Disposed/sold 24,999 options to buy @ $29.4, valued at $735k
Granted 24,999 options to buy @ $2.77, valued at $69.2k
Disposed/sold 15,000 options to buy @ $59.75, valued at $896.3k
Granted 15,000 options to buy @ $2.77, valued at $41.6k
Disposed/sold 29,000 options to buy @ $41.8, valued at $1.2M
Granted 29,000 options to buy @ $2.77, valued at $80.3k
Disposed/sold 56,666 options to buy @ $10.6, valued at $600.7k
Granted 56,666 options to buy @ $2.77, valued at $157k
05/10/2023 SC 13G/A FMR LLC reports a 4% stake in UNITY BIOTECHNOLOGY INC
05/09/2023 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., May 9, 2023 --"
05/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/03/2023 144 Form 144 - Report of proposed sale of securities:
05/02/2023 4 Ghosh Anirvan (CEO) has filed a Form 4 on Unity Biotechnology, Inc.
Txns: Sold 1,020 shares @ $2.15, valued at $2.2k
05/02/2023 144 Form 144 - Report of proposed sale of securities:
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/24/2023 8-K Quarterly results
04/03/2023 4 Ghosh Anirvan (CEO) has filed a Form 4 on Unity Biotechnology, Inc.
Txns: Sold 1,959 shares @ $1.7, valued at $3.3k
04/03/2023 4 Dananberg Jamie (Chief Medical Officer) has filed a Form 4 on Unity Biotechnology, Inc.
Txns: Sold 420 shares @ $1.7, valued at $714
03/27/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration UBX1325 monotherapy did not achieve non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain in the anti-VEGF control arm UBX1325 maintained visual acuity in patients with ongoing active disease through 24 weeks with less than one letter mean decrease from baseline 52% of UBX1325-treated patients did not require anti-VEGF treatment through 24 weeks Company to share 48-week BEHOLD DME data in April and intends to initiate Phase 2b study in DME in second half of 2023 UNITY to host investor call today, March 27, at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., March 27, 2023",
"4 0 2 4 8 12 16 20 24 28 32 36 40 44 48"
03/17/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment No. 2 to Sales Agreement, by and between Unity Biotechnology, Inc. and Cowen and Company, LLC",
"Amendment No. 2 to Sales Agreement, by and between Unity Biotechnology, Inc. and Cowen and Company, LLC"
03/17/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/15/2023 4 Dananberg Jamie (Chief Medical Officer) has filed a Form 4 on Unity Biotechnology, Inc.
Txns: Sold 1,005 shares @ $4, valued at $4k
03/15/2023 4 Ghosh Anirvan (CEO) has filed a Form 4 on Unity Biotechnology, Inc.
Txns: Sold 1,210 shares @ $4, valued at $4.8k
03/15/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/15/2023 10-K Annual Report for the period ended December 31, 2022
03/15/2023 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., March 15, 2023 --"
02/14/2023 SC 13G Alyeska Investment Group, L.P. reports a 10% stake in Unity Biotechnology, Inc.
02/09/2023 SC 13G/A FMR LLC reports a 9.2% stake in UNITY BIOTECHNOLOGY INC
02/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/31/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy